Aortic regurgitation, also known as aortic insufficiency, is a heart valve disorder characterized by the leakage of blood backward through the aortic valve each time the left ventricle of the heart relaxes. This condition can be caused by various factors, including congenital abnormalities, rheumatic fever, infections, or age-related wear and tear on the valve. As blood flows back into the left ventricle, the heart must work harder to pump an adequate amount of blood to the body, leading to potential complications over time. Symptoms of aortic regurgitation may include fatigue, shortness of breath, and chest pain. Diagnosis often involves a combination of medical history review, physical examination, and imaging studies such as echocardiography. Treatment options depend on the severity of the regurgitation and may range from medication management to surgical interventions, including valve repair or replacement. Regular monitoring and timely intervention are crucial to managing aortic regurgitation effectively and preventing further complications. Patients with this condition often benefit from close collaboration with a cardiovascular healthcare team to ensure optimal heart health and overall well-being.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India